These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 14760175)
21. Reactions to infliximab in patients with rheumatoid arthritis. Sakellariou GT; Chatzigiannis I J Rheumatol; 2005 Jul; 32(7):1411-2. PubMed ID: 15996088 [No Abstract] [Full Text] [Related]
22. Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors. Segan J; Staples MP; March L; Lassere M; Chakravarty EF; Buchbinder R Intern Med J; 2015 Mar; 45(3):310-8. PubMed ID: 25565419 [TBL] [Abstract][Full Text] [Related]
24. Occurrence of pulmonary thromboembolism during infliximab therapy. Eklund KK; Peltomaa R; Leirisalo-Repo M Clin Exp Rheumatol; 2003; 21(5):679. PubMed ID: 14611130 [No Abstract] [Full Text] [Related]
25. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Musiał J; Undas A; Celińska-Lowenhoff M Rheumatology (Oxford); 2003 Dec; 42(12):1566-8. PubMed ID: 14645861 [No Abstract] [Full Text] [Related]
26. Morbidity and mortality in rheumatoid patients during treatment with adalimumab and infliximab. Molloy E; Ramakrishnan S; Murphy E; Barry M Rheumatology (Oxford); 2004 Apr; 43(4):522-3. PubMed ID: 15024136 [No Abstract] [Full Text] [Related]
32. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Favalli EG; Sinigaglia L; Varenna M; Arnoldi C Lupus; 2002; 11(11):753-5. PubMed ID: 12475006 [TBL] [Abstract][Full Text] [Related]
33. Reactivation of brucellosis after treatment with infliximab in a patient with rheumatoid arthritis. Jiménez FG; Colmenero JD; Irigoyen MV J Infect; 2005 May; 50(4):370-1. PubMed ID: 15845443 [No Abstract] [Full Text] [Related]
34. Haemophagocytic syndrome in a rheumatoid arthritis patient treated with infliximab. Aouba A; De Bandt M; Aslangul E; Atkhen N; Patri B Rheumatology (Oxford); 2003 Jun; 42(6):800-2. PubMed ID: 12771439 [No Abstract] [Full Text] [Related]
35. Infliximab-induced vitiligo. Ramírez-Hernández M; Marras C; Martínez-Escribano JA Dermatology; 2005; 210(1):79-80. PubMed ID: 15604556 [No Abstract] [Full Text] [Related]
36. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. Hochman D; Wolff B JAMA; 2006 Nov; 296(18):2203; author reply 2203-4. PubMed ID: 17090763 [No Abstract] [Full Text] [Related]
37. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. Callegari PE; Schaible TF; Boscia JA JAMA; 2006 Nov; 296(18):2202; author reply 2203-4. PubMed ID: 17090762 [No Abstract] [Full Text] [Related]
38. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. Costenbader KH; Glass R; Cui J; Shadick N JAMA; 2006 Nov; 296(18):2201; author reply 2203-4. PubMed ID: 17090761 [No Abstract] [Full Text] [Related]
39. Severe interstitial pneumonitis associated with infliximab therapy. Chatterjee S Scand J Rheumatol; 2004; 33(4):276-7. PubMed ID: 15370726 [No Abstract] [Full Text] [Related]
40. Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis. Vandevyvere K; Luyten FP; Verschueren P; Lories R; Segaert S; Westhovens R Clin Rheumatol; 2007 Dec; 26(12):2205-2206. PubMed ID: 17876646 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]